19 JUNE 2014 NEW ZEALAND GAZETTE, No. 65

Terbinafine; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Tioconazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Medicines for General Sale

Please note that the following medicines are now available for general sale.

Adrenaline; in medicines for injection containing 0.02% or less

Amorolfine; in preparations for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

C1 esterase inhibitors

Cetirizine; in divided solid dosage forms for oral use containing 10 milligrams or less of cetirizine hydrochloride per dose form for the treatment of seasonal allergic rhinitis when sold in the manufacturer’s original pack containing not more than 5 days’ supply

Ciclopirox; for external use in medicines containing 2% or less when for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Clotrimazole; for external use in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Diclofenac; in preparations for external use other than for the treatment of solar keratosis

Econazole; for dermal use in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Factor VIII inhibitor bypassing fraction

Fexofenadine; for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing 10 dosage units or less and not more than 5 days’ supply

Guaiphenesin; for oral use in medicines containing 2% or less or 200 milligrams or less per dose form; for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams when sold in the manufacturer’s original pack containing not more than 10 days’ supply

Human protein C

Ibuprofen; for external use; in divided solid dosage forms for oral use containing 200 milligrams or less per dose form with a recommended daily dose of not more than 1.2 grams and when sold in the manufacturer’s original pack containing not more than 25 dose units per pack

Isoconazole; for dermal use when sold in practice by a podiatrist registered with the Podiatrists Board

Ketoconazole; for dermal use in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board; in medicines for treatment of the scalp containing 1% or less

Loratadine; in divided solid dosage forms for oral use containing 10 milligrams or less per dose form for the treatment of seasonal allergic rhinitis when sold in the manufacturer’s original pack containing not more than 5 days’ supply

Mepyramine; for external use in medicines containing 2% or less in packs not exceeding 25 grams

Miconazole; for external use in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Nystatin; for dermal use when sold in practice by a podiatrist registered with the Podiatrists Board

Oxymetazoline; for nasal use, when sold in the manufacturer’s original pack containing not more than 20 millilitres

Ranitidine; in medicines containing 150 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than 7 days’ supply

Terbinafine; for dermal use in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Tioconazole; for dermal use in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Dated this 18th day of June 2014.

DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health.

go3807

Social Security Act 1964

Maximum Contribution Applying in Each Territorial Local Authority Region from 1 July 2014

Under section 152 of the Social Security Act 1964, the Director-General of Health is required to notify the maximum contribution that applies in each region for long-term aged residential care.

The maximum contribution is the maximum weekly amount (inclusive of GST) that a resident assessed as requiring long-term residential care (through a needs assessment and service coordination agency) is required to pay for contracted care services provided to them in the region in which their rest home or continuing care hospital is located.

Contracted care services are services provided to needs-assessed people in a rest home or continuing care hospital that has a contract with a district health board.

The services provided are those necessary to meet the person’s assessed care needs in accordance with the agreement between the district health board and the residential care provider.

This agreement covers residents who are:

• eligible for the residential care subsidy (under section 141 of the Act); or
• entitled to have funding paid to cover the difference between the maximum contribution and the cost of contracted care services provided to them (under section 140 of the Act).

The maximum contribution is the same for all residents regardless of the type of contracted care services they receive.